AMGN - アムジェン (Amgen Inc.) アムジェン

 AMGNのチャート


 AMGNの企業情報

symbol AMGN
会社名 Amgen In (アムジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta(ペグフィルグラスチム)、Aranesp(ダルベポエチンアルファ)・EPOGEN(エポエチンアルファ)等の赤血球産生促進剤(ESAs)、Sensipar/Mimpara(シナカルセット)、XGEVA(デノスマブ)、Prolia(デノスマブ)及びNEUPOGEN(フィルグラスチム)、並びにKYPROLIS(カルミゾミブ)、Vectibix(パニツムマブ)、Nplate(ロムリプスチム)、Repatha(エボロクマブ)、BLINCYTO(ブリナトモマブ)、IMLYGIC(タルミモジュラーラパーパープ)、Corlanor(イバブラジン)など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。   アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤「アラネスプ」、白血球減少症治療剤「ニュ―ラスタ」など。  Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
本社所在地 One Amgen Center Drive Thousand Oaks CA 91320-1799 USA
代表者氏名 Robert A. Bradway ロバート・A・ブラッドウェイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 805-447-1000
設立年月日 29312
市場名 NASDAQ National Market System
ipoyear 1983年
従業員数 20800人
url www.amgen.com
nasdaq_url https://www.nasdaq.com/symbol/amgn
adr_tso
EBITDA EBITDA(百万ドル) 12110
終値(lastsale) 205.72
時価総額(marketcap) 133156809623.24
時価総額 時価総額(百万ドル) 133338
売上高 売上高(百万ドル) 23188
企業価値(EV) 企業価値(EV)(百万ドル) 138440
当期純利益 当期純利益(百万ドル) 8464
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.

 AMGNのテクニカル分析


 AMGNのニュース

   Amgen''s Lumakras Shows Two-Year Overall Survival Of 32.5% In KRAS-Mutated Lung Cancer  2022/04/11 16:13:05 Benzinga
Amgen Inc (NASDAQ: AMGN ) announced the presentation of long-term data from the CodeBreaK 100 Phase 1/2 trial of Lumakras (sotorasib) in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). In the long-term, two-year analysis of 174 heavily pretreated patients, Lumakras demonstrated a centrally confirmed objective response rate (ORR) of 40.7%, … Full story available on Benzinga.com
   Amgen und Biogen: Schlagen diese beiden Biotech-Urgesteine bald zurck?  2022/04/11 16:00:06 FinanzenNet
piframe title="Amgen und Biogen Schlagen diese beiden Biotech-Urgesteine bald zurck?" width="475" height="267" src="https://www.youtube.com/embed/abu7F90gWEM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; …/p
   TSX Steps Back from All-Time Highs  2022/04/06 20:23:00 Baystreet Canada
Equities in North America displayed their nerves Wednesday, with central banks openly discussing rate hikes for the very near future. The TSX Composite Index lost 142.23 points to conclude midweek Wednesday at 21,788.60. The Canadian dollar fell 0.31 cents to 79.79 cents U.S. Tech proved the biggest anchor on the index, with Lightspeed POS down $3.07, or 7.7%, to $36.63, and Shopify sagged $54.61, or 6.3%, to $823.86. Real-estate was also a worry, as InterRent REIT dropped 57 cents, or 3.8%, to $14.57, while Allied Properties REIT faltered $1.45, or 3.1%, to $44.69. In energy, Whitecap Resources moved earthward 48 cents, or 4.6%, to $9.88, while Vermilion Energy slid $1.58, or 5.9%, to $25.27. Utilities was strongest fop the gainers, as Transalta copped 50 cents, or 3.8%, to $13.57, while Boralex advanced $1.96 or 3.4%, to $41.56. Communications became green in the afternoon, with Quebecor tacking on 76 cents, or 2.5%, to $31.27, while Cogeco Communications moved forward $1.51, or 1.4%, to $105.86.
   Fed Tightening Weighs on Markets  2022/04/06 20:23:00 Baystreet Canada
Stocks fell for a second day on Wednesday and rates soared to new heights as the Federal Reserve gave more guidance on how fast it will tighten monetary policy to fight inflation, raising concerns it may slow the economy. The Dow Jones Industrials plummeted 144.67 to end the session at 34,496.51. The S&P 500 dumped 43.97 points to 4,481.15 The NASDAQ Composite wilted 315.35 points, or 2.2%, to 13,888.82. The Fed’s release of its meeting minutes indicated on Wednesday afternoon that officials “generally agreed” it should shrink its balance sheet by $95 billion per month. The minutes also showed the central bank was considering larger rate hikes than its usual 25-basis-point, or quarter-point, increments. As the Fed hikes rates, investors have begun searching for stocks with stable profits and shying away from those offering future growth. That includes the utilities, health care and consumer staples sectors — which continued to climb Wednesday, with Amgen and Johnson & Johnson rising about 2% each.
   Is Amgen Inc. (NASDAQ: AMGN) Still A Good Investment?  2022/04/06 17:00:00 Stocks Register
Amgen Inc. (NASDAQ:AMGN) traded at $250.15 at last check on Wednesday, April 06, made an upward move of 2.29% on its previous day’s price. Looking at the stock we see that its previous close was $244.56 and the beta (5Y monthly) reads 0.64 with the day’s price range being $243.74 – $248.75. The company has … Is Amgen Inc. (NASDAQ: AMGN) Still A Good Investment? Read More »
   Oregon Public Employees Retirement Fund Sells 4,563 Shares of Amgen Inc. (NASDAQ:AMGN)  2021/12/02 20:10:43 Transcript Daily
Oregon Public Employees Retirement Fund trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 121,695 shares of the medical research companys stock after selling 4,563 shares during the period. []
   Amgen Inc. (NASDAQ:AMGN) Shares Sold by Albion Financial Group UT  2021/12/02 17:46:43 Transcript Daily
Albion Financial Group UT lowered its position in Amgen Inc. (NASDAQ:AMGN) by 0.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,387 shares of the medical research companys stock after selling 110 shares during the quarter. Albion Financial Group UTs holdings in Amgen were []
   Amgen Reveals Topline Results from Otezla Phase 3 DISCREET Study  2021/12/02 12:29:08 Smarter Analyst
This article was originally published on TipRanks.com Amgen (AMGN) has revealed positive topline results from the Phase 3 DISCREET trial. The post Amgen Reveals Topline Results from Otezla Phase 3 DISCREET Study appeared first on Smarter Analyst .
   Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK)  2021/12/02 12:10:17 Wall Street PR
With the spotlight firmly on Covid variants, its easy to lose sight of what will probably be the most important segment of the biopharma space over the next ten years: oncology. This is where the biggest success stories will be found. Its where the largest revolutions will happen. Its the epicenter of the most important [] The post Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LLY, GILD, MRK) appeared first on Wall Street PR .
   Amgen''s Otezla Meets Primary Goal In Late-Stage Genital Psoriasis Study  2021/12/02 11:21:53 Benzinga
Amgen Inc (NASDAQ: AMGN ) announced topline results from the DISCREET trial Phase 3 trial of Otezla (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, Full story available on Benzinga.com
   Leap Therapeutics, AstraZeneca Shares Get Boost From Cancer Presentations  2021/09/29 19:40:45 GuruFocus
Stocks climb after companies report encouraging study data Related Stocks: LPTX , AZN , CRVS , SURF , JAZZ , VSTM , AMGN , BYSI , IPHA , MGNX , SBTX , TSE:4568 , LSE:REDX , SYRS ,
   Women''s Health Care Drugs Market to Set Phenomenal Growth from 2021 to 2026 | Ferring B.V., Pfizer, Merck & Co., Agile Therapeutics, AstraZeneca, Amgen  2021/09/29 17:47:37 OpenPR
Latest update report on Women''s Health Care Drugs Market Size, Share, Growth, Industry Trends and Forecast by 2028. This report is highly predictive as it holds the overall market analysis of the topmost companies into the Women''s Health Care Drugs
   Wearbale Injectors Market : Moving Towards Brighter Future | Major Giants Amgen Inc., Medtronic, Insulet Corporation, Ypsomed, BD  2021/09/29 17:16:09 OpenPR
The world class Wearbale Injectors Market report studies extensive evaluation of the market growth predictions and restrictions. The strategies range from new product launches, expansions, agreements, joint ventures, partnerships, to acquisitions. This report comprises of a deep knowledge and information
   Novel Drug Delivery Systems Market Competitive Insights and Precise Outlook 2021- Amgen, Teva, Roche, UCB (Union Chimique Belge), Celgene  2021/09/29 09:04:31 OpenPR
The "Novel Drug Delivery Systems" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Novel Drug Delivery Systems Industry presents a market overview,
   The Economist Group launches Economist Impact  2021/09/28 23:00:00 PR Newswire Asia (English)
LONDON , Sept. 29, 2021 /PRNewswire/ -- The Economist Group has today announced the launch of Economist Impact -- a business which will partner with leading corporations, governments and nonprofits to deliver positive societal change. In a unique offering, Economist Impact brings together a 75-year heritage of evidence-based policy research with the creativity of a trusted media brand to engage an unrivalled global audience of influential executives. Economist Impact delivers the insight, innovation and influence decision makers need to catalyse progress in our rapidly evolving world. Together with its partners, Economist Impact drives the conversation around three key areas of systemic transformation -- sustainability, health and the changing shape of globalisation -- and is already designing multi-year partnerships for a spectrum of clients, with a global stage enabling them to play a leading role. Examples include the Back to Blue initiative with The Nippon Foundation, which aims to protect the health of oceans, and Google Jigsaw''s programme to end online violence against women.

 関連キーワード  (医薬品 米国株 アムジェン AMGN Amgen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)